AtriCure (ATRC) Set to Announce Quarterly Earnings on Wednesday

AtriCure (NASDAQ:ATRC) will release its earnings data after the market closes on Wednesday, May 1st. Analysts expect AtriCure to post earnings of ($0.20) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, February 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The firm had revenue of $106.50 million during the quarter, compared to analyst estimates of $103.68 million. During the same period in the previous year, the business posted ($0.09) EPS. AtriCure’s revenue was up 21.0% on a year-over-year basis. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $23.37 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.66 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $29.64 and its two-hundred day moving average is $33.47. The firm has a market capitalization of $1.13 billion, a P/E ratio of -35.41 and a beta of 1.38. AtriCure has a 52 week low of $22.07 and a 52 week high of $59.61.

Insiders Place Their Bets

In other news, insider Justin J. Noznesky sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the completion of the transaction, the insider now owns 74,284 shares in the company, valued at approximately $2,727,708.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Karl S. Dahlquist sold 1,885 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $32.16, for a total transaction of $60,621.60. Following the sale, the insider now directly owns 50,954 shares of the company’s stock, valued at $1,638,680.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Justin J. Noznesky sold 1,500 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total value of $55,080.00. Following the completion of the transaction, the insider now owns 74,284 shares of the company’s stock, valued at approximately $2,727,708.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,116 shares of company stock worth $468,797. 3.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on ATRC. UBS Group lifted their target price on AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, February 16th. Oppenheimer upgraded shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research note on Tuesday, April 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 target price on shares of AtriCure in a research report on Wednesday, April 10th. StockNews.com downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th. Finally, Stifel Nicolaus reduced their price target on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, February 16th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $52.63.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.